Efficiency of antiretroviral therapy for HIV infection



Cite item

Full Text

Abstract

The authors give the results of studying the efficiency of standard highly active antiretroviral therapy (HAART) regiments in patients with HIV infection. The findings suggest that longevity in HIV-infected patients receiving HAART is 2 times higher than in untreated patients. At the same time, the best treatment results were obtained at the beginning of HAART in patients with higher CD4+ lymphocyte levels and the choice of the first therapy regimen failed to affect therapeutic effectiveness. The change of the first treatment regimen was mainly associated with adverse reactions. Treatment was ineffective in only 1.4% of cases due to the developed resistance to antiviral agents.

About the authors

G F Moshkovich

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

S V Minayeva

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Email: mistella@yandex.ru
Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

L V Varlova

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

M P Goryaeva

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

I D Voronina

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Ye V Tikhonova

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Nizhni Novgorod

References

  1. Клинические рекомендации. ВИЧ-инфекция и СПИД / Под ред. В. В. Покровского. - М., 2006.
  2. Первичная лекарственная устойчивость ВИЧ-1 в Европе остается ограниченной отдельными классами препаратов (реферат). // AIDS. - 2008. - Vol. 28. - P. 625-635.
  3. Покровский В. В. ВИЧ/СПИД в России: ситуация и прогноз // Эпидемиол. и инфекц. бол. - 2008. - № 3. - С. 4- 7.
  4. Badri M., Lawn S. D., Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study // Lancet. - 2006. - Vol. 368. - P. 1254-1259.
  5. Bangsberg D., Moss A., Deeks S. Paradoxes of adherence and drug resistance to HIV antiretroviral thetapy // J. Antimicrob. Chemother. - 2004. - Vol. 53. - P. 696-699.
  6. Bannister W. P., Mocroft A. et al. Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients // 9-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 9-13 Nov., 2008. - Glazgow, 2008. - P. 13.
  7. Calmy A., Pinogues I., Szumilin E. et al. Genetic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort // AIDS. - 2006. - Vol. 20. - P. 1163-1169.
  8. Chen S. Y., McFarland W. HAART treatment and CD4 count: when to initiate? // 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July, 2003. - Paris, 2003. - P. 339.
  9. Crum N. F., Riffenburgh R. H., Wegner S. et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early and late HAART eras // J. Acquir. Immune Defic. Syndr. - 2006. - Vol. 41. - P. 194-200.
  10. El-Sadr W. M., Lundgren J. D., ,Neaton J. D. et al. CD4 count-guided interruption of antiretroviral treatment // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2283-2296.
  11. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. - Washington, 2006.
  12. Gulick R. M. Where are we with ART in 2006? // 8-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 12-16 Nov., 2006. - Glazgow, 2006. - P. 1.
  13. Heckman B. D., Catz S. L., Heckman T. G. et al. Adherence to antiretroviral therapy in rural persons living with HIV disease in the United States // AIDS Care. - 2004. - Vol. 16. - P. 219-230.
  14. Huang H. Y., Daar E. S. et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection. // HIV Med. - 2008. - Vol. 9. - P. 285-293.
  15. Levin A. The risk of non-AIDS defining malignancies in the era of highly active antiretroviral therapy (HAART) // 8-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 12-16 Nov., 2006. - Glazgow, 2006. - P. 8.
  16. MacArthur R. D., Novak R. M., Peng G. et al. A comparison of HAART strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy: a long-term randomized trial // Lancet. - 2006. - Vol. 368. - P. 2125-2135.
  17. Minaeva S., Moshkovich G. An HIV-patient has refused to proceed with HAART: reasons, upshots, and further strategy // 8-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 12-16 Nov., 2006. - Glazgow, 2006. - P. 64.
  18. Mocroft A., Ledergerber B., Katlama C. et al. Decline in the AIDS and death rates in the EuroSIDA Study: an observational study // Lancet. - 2003. - Vol. 362. - P. 22-29.
  19. Mocroft A., Phillips A. N., Soriano V. et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/ physician choice in patients with hepatitis C coinfection // AIDS Res. Hum. Retrovirus. - 2005. - Vol. 21. - P. 743-752.
  20. Sighem A., Ghani A., Reiss P. et al. Mortality after starting highly active antiretroviral therapy // 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July, 2003. - Paris, 2003. - P. 208.
  21. Silverberg M. J., Neuhaus J., Bower M. et al. Risk of cancer during interrupted antiretroviral therapy in the SMART study // AIDS. - 2007. - Vol. 21. - P. 1957-1963.
  22. Wood R. HIV/TB: when is it safe to start HAART? // 9-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 9-13 Nov., 2008. - Glazgow, 2008. - P. 5.

Copyright (c) 2010 Eco-vector



Свидетельство о регистрации СМИ № 014448 от 08.02.1996 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор). 
Свидетельство о регистрации СМИ ЭЛ № ФС 77 - 80652 от 15.03.2021 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies